Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …

Abstract Exportin 1 (XPO1), also known as chromosome region maintenance protein 1,
plays a crucial role in maintaining cellular homeostasis via the regulated export of a range of …

Lenvatinib is the first target drug approved for advanced hepatocellular carcinoma (HCC).
However, the development of drug resistance is common, and the mechanisms of lenvatinib …

Background: Lenvatinib is in a first-line therapy for advanced hepatocellular carcinoma
(HCC). However, drug resistance is one of the principal obstacles for treatment failure. The …

The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs)
has undergone major advancements in the last decade, causing a paradigm shift in the …

Purpose Selinexor is a novel XPO1 inhibitor which inhibits the export of tumor suppressor
proteins and oncoprotein mRNAs, leading to cell-cycle arrest and apoptosis in cancer cells …

Gastric cancer is one of the most common malignant tumors in the world. In China, its
morbidity and mortality are second only to lung cancer. Chemotherapy combined with …

Lenvatinib is a multitargeted tyrosine kinase inhibitor capable of promoting apoptosis,
suppressing angiogenesis, inhibiting tumor cell proliferation, and modulating the immune …

Lenvatinib (LVN) has been appoved to treat advanced renal cell carcinoma, differentiated
thyroid carcinoma, hepatocellular carcinoma. Further other cancer types also have been …